Universitaet Leipzig — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

6 Recruiting

4 Completed trials

2 Countries active

22 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 6 Phase IV: 2

Oversight events:

1 temporary halt 1 corrective measure across 2 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gastrectomy 1 Status epilepticus 1

Top IMPs

AMYLASE, PROTEASE, RIZOLIPASE 1 AZACITIDINE 1 BLINATUMOMAB 1 CANAKINUMAB 1 CYTARABINE 1 CYTARABINE, DAUNORUBICIN 1 DAUNORUBICIN HYDROCHLORIDE 1 HU5F9‐G4 1 IODIXANOL 1 IOHEXOL 1 IOMEPROL 1 IOPAMIDOL 1

All trials

10 total

A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatmen… Recruiting

2025-523061-22-00 Phase II 1 country BLINATUMOMAB
A contrast medium sparing strategy using automated Carbon Dioxide Injection during PERIpheral vascular interventions for PREVENTion of Major… Recruiting

2024-512876-37-00 Phase III 2 countries IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSOL
European Larynx Organ Preservation Study (ELOS) Recruiting

2022-502751-61-00 Phase II 1 country PEMBROLIZUMAB
Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial Recruiting

2024-516634-35-00 Phase IV 1 country
The Pancreatic Enzymes after Gastrectomy Trial Recruiting

2022-501944-14-00 Phase III 1 country AMYLASE, PROTEASE, RIZOLIPASE
Cholangiocarcinoma treatment with radiofrequency ablation or photodynamic therapy Recruiting

2022-500107-50-00 Phase IV 1 country
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Phase II 1 country LUSPATERCEPT
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients with IPSS-… Ended

2024-515886-33-00 Phase II 1 country CANAKINUMAB
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen… Ended

2022-501537-23-00 Phase II 1 country AZACITIDINE; VENETOCLAX
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended

2022-502040-13-00 Phase II 1 country CYTARABINE; CYTARABINE, DAUNORUBICIN; DAUNORUBICIN HYDROCHLORIDE; HU5F9‐G4

Showing 1–10 of 10 trials

← All sponsors A–Z